- Home
- OCEAW vs CMMB Comparison
OCEAW vs CMMB Comparison
Compare OCEAW & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCEAW
- CMMB
- Stock Information
- Founded
- OCEAW N/A
- CMMB 2004
- Country
- OCEAW United States
- CMMB Israel
- Employees
- OCEAW 7
- CMMB N/A
- Industry
- OCEAW Biotechnology: Pharmaceutical Preparations
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- OCEAW Health Care
- CMMB Health Care
- Exchange
- OCEAW Nasdaq
- CMMB Nasdaq
- Market Cap
- OCEAW N/A
- CMMB 23.6M
- IPO Year
- OCEAW 2021
- CMMB N/A
- Fundamental
- Price
- OCEAW $0.03
- CMMB $1.39
- Analyst Decision
- OCEAW
- CMMB Strong Buy
- Analyst Count
- OCEAW 0
- CMMB 2
- Target Price
- OCEAW N/A
- CMMB $9.00
- AVG Volume (30 Days)
- OCEAW N/A
- CMMB 863.6K
- Earning Date
- OCEAW N/A
- CMMB 03-03-2025
- Dividend Yield
- OCEAW N/A
- CMMB N/A
- EPS Growth
- OCEAW N/A
- CMMB N/A
- EPS
- OCEAW N/A
- CMMB N/A
- Revenue
- OCEAW N/A
- CMMB N/A
- Revenue This Year
- OCEAW N/A
- CMMB N/A
- Revenue Next Year
- OCEAW N/A
- CMMB N/A
- P/E Ratio
- OCEAW N/A
- CMMB N/A
- Revenue Growth
- OCEAW N/A
- CMMB N/A
- 52 Week Low
- OCEAW N/A
- CMMB $0.58
- 52 Week High
- OCEAW N/A
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- OCEAW N/A
- CMMB 38.56
- Support Level
- OCEAW N/A
- CMMB $1.21
- Resistance Level
- OCEAW N/A
- CMMB $1.54
- Average True Range (ATR)
- OCEAW 0.00
- CMMB 0.16
- MACD
- OCEAW 0.00
- CMMB -0.01
- Stochastic Oscillator
- OCEAW 0.00
- CMMB 32.73
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.